Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

479
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
479
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Risk Score Based on Lipid-Related Biomarkers for Acute Coronary Syndromes: A Multicenter Machine Learning Study.

Reviews in cardiovascular medicine·2026
Same author

Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.

Circulation·2026
Same author

Analysis of the Correlation Between Cuproptosis and Instability of Atherosclerotic Plaques.

Biomedicines·2025
Same author

Blocking nuclear receptor Nr4a3 unlocks the senescence barrier to promote direct cardiac reprogramming.

Science advances·2025
Same author

Coupling of USP10 de-ubiquitination and chaperone-mediated autophagy causes cardiac sodium channel degradation and cardiac arrhythmias.

Cardiovascular research·2025
Same author

Cardioneuroablation for coronary artery vasospasm: a case report.

European heart journal. Case reports·2025

Related Experiment Video

Updated: Jan 9, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Metabolic Modulation in Dilated Cardiomyopathy: From Pathophysiology to Therapy.

Xiang Nie1,2,3, Zhibing Lu1,2,3

  • 1Department of Cardiology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, Hubei, China.

Reviews in Cardiovascular Medicine
|December 8, 2025
PubMed
Summary
This summary is machine-generated.

Dilated cardiomyopathy (DCM) pathogenesis involves disrupted cardiac energy metabolism, affecting blood flow and substrate use. Targeting energy pathways offers new therapeutic strategies for heart failure.

Keywords:
dilated cardiomyopathyenergy supply and metabolismgenetic mutationmyocardial blood flow

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K

Related Experiment Videos

Last Updated: Jan 9, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K

Area of Science:

  • Cardiology
  • Metabolic Research
  • Biochemistry

Background:

  • Dilated cardiomyopathy (DCM) is characterized by myocardial structural and functional impairments.
  • Causes include genetic mutations (e.g., TTN, lamin) and acquired factors (infection, alcohol, drugs, endocrine disorders).
  • Disrupted cardiac energy homeostasis is central to DCM pathogenesis, leading to contractile dysfunction.

Purpose of the Study:

  • To synthesize evidence on cardiac energy metabolism's role in DCM pathogenesis.
  • To focus on myocardial blood flow, substrate utilization, and metabolic pathways.
  • To explore potential energy-targeted therapeutic strategies for DCM.

Main Methods:

  • Review of current scientific literature and evidence.
  • Synthesis of data on genetic and acquired factors in DCM.
  • Analysis of myocardial energetics and adenosine triphosphate (ATP) production.

Main Results:

  • Impaired myocardial energetics, reduced coronary blood flow, and altered substrate metabolism are hallmark features of DCM.
  • Energy deficiency is increasingly recognized as a key driver of DCM development and heart failure.
  • Cardiac energy metabolic disruption is integral to DCM pathophysiology.

Conclusions:

  • Cardiac energy metabolic disruption is a promising target for novel therapeutic interventions in DCM.
  • Current DCM management often overlooks metabolic aspects.
  • Integrating energy-based approaches into DCM treatment is needed.